CA3115269A1 - Combination of ibudilast and interferon-beta and methods of using same - Google Patents

Combination of ibudilast and interferon-beta and methods of using same Download PDF

Info

Publication number
CA3115269A1
CA3115269A1 CA3115269A CA3115269A CA3115269A1 CA 3115269 A1 CA3115269 A1 CA 3115269A1 CA 3115269 A CA3115269 A CA 3115269A CA 3115269 A CA3115269 A CA 3115269A CA 3115269 A1 CA3115269 A1 CA 3115269A1
Authority
CA
Canada
Prior art keywords
interferon
beta
ibudilast
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3115269A
Other languages
English (en)
French (fr)
Inventor
Kazuko Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CA3115269A1 publication Critical patent/CA3115269A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3115269A 2018-10-09 2019-10-08 Combination of ibudilast and interferon-beta and methods of using same Pending CA3115269A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743449P 2018-10-09 2018-10-09
US62/743,449 2018-10-09
PCT/US2019/055167 WO2020076809A1 (en) 2018-10-09 2019-10-08 Combination of ibudilast and interferon-beta and methods of using same

Publications (1)

Publication Number Publication Date
CA3115269A1 true CA3115269A1 (en) 2020-04-16

Family

ID=68343518

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3115269A Pending CA3115269A1 (en) 2018-10-09 2019-10-08 Combination of ibudilast and interferon-beta and methods of using same

Country Status (7)

Country Link
US (1) US10946071B2 (enExample)
EP (1) EP3863628B1 (enExample)
JP (1) JP2022504435A (enExample)
CN (1) CN112770748A (enExample)
CA (1) CA3115269A1 (enExample)
ES (1) ES2973119T3 (enExample)
WO (1) WO2020076809A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231998T3 (es) 1998-08-10 2005-05-16 Kyorin Pharmaceutical Co., Ltd. Medicina para la esclerosis multiple.
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
US7534806B2 (en) 2004-12-06 2009-05-19 Avigen, Inc. Method for treating neuropathic pain and associated syndromes
HRP20120382T1 (hr) * 2006-05-24 2012-06-30 Merck Serono Sa Kombinacija davanja interferona-beta i kladribina za liječenje multiple skleroze
PT2187882E (pt) 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
EP2648732A4 (en) * 2010-12-07 2014-04-30 Teva Pharma USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate

Also Published As

Publication number Publication date
WO2020076809A1 (en) 2020-04-16
US10946071B2 (en) 2021-03-16
US20200108123A1 (en) 2020-04-09
JP2022504435A (ja) 2022-01-13
EP3863628A1 (en) 2021-08-18
ES2973119T3 (es) 2024-06-18
EP3863628B1 (en) 2023-12-27
CN112770748A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
US11944607B2 (en) Treatment of progressive neurodegenerative disease with ibudilast
EP3752147A1 (en) Methods and dosing regimens using ibudilast and a second agent for cancer therapy
US10946071B2 (en) Combination of ibudilast and interferon-beta and methods of using same
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
EP3866788B1 (en) Treatment of macular injury associated with multiple sclerosis with ibudilast